Lupus patients who adhere to medications have lower risk of type 2 diabetes

Lupus patients who adhere to medications have lower risk of type 2 diabetes

UTHSC researchers receive $1.98 million grant for novel approach to studying diabetes For the protective effect to apply, the patient should take their prescriptions at least 90 per cent of the time--refilling on time and not skipping medications, the researchers found. "It's not enough to take your meds a few times, you need to take them faithfully," adds de Vera. "Our finding suggests that the benefits hinge on adhering to the treatment plan for as long as required." The researchers analyzed data on 1,498 lupus patients in British Columbia, comparing prescriptions, healthcare visits and hospitalizations over a period of four years. "Prior to this study, we already found that from 43 per cent to 75 per cent of lupus patients do not take their medications as prescribed. What we didn't know was what the impact of that was on diabetes, which is a serious complication. Now, for the first time, we have a good idea," notes de Vera, a research scientist with Arthritis Research Canada. De Vera and her colleagues are also currently studying why patients take or do not take medications, and looking for ways to better support them. "For people with lupus, preventing type 2 diabetes is critical. Diabetes can lead to many other complications such as neuropathy, cardiovascular disease and kidney failure. Given the clear implications of non-adherence to lupus treatment, future research should focus on developing and testing ways to improve antimalarial adherence," says de Vera. The study was recently published in Arthritis Care & Research . Source: University of British Columbia Journal reference: Salmasi, S, et al. (2020) Adherence to Antimalarial Therapy and Risk of Type 2 Diabetes Mellitus among Patients with Systemic Lupus Erythematosus: A Population‐Based Study. Arthritis Care & Research . doi.org/10.1002/acr.24147 .



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More